# ProMIS Neurosciences Inc.: overview PMN · Nasdaq · CIK 1374339 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/pmn.md) · [Financials](/companies/pmn/financials.md) · [Filings](/companies/pmn/filings.md) · [Insiders](/companies/pmn/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [0.31](/filings/0001104659-25-109719.md) | not reported | [(5.27)](/filings/0001104659-26-059035.md) | [(7.26)](/filings/0001104659-26-095895.md) | [(0.24)](/filings/0001104659-25-109719.md) | not reported | [(1.26)](/filings/0001104659-26-059035.md) | [(1.28)](/filings/0001104659-26-095895.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.69)](/filings/0001558370-23-003167.md) | [(2.41)](/filings/0001558370-24-004532.md) | [(1.07)](/filings/0001558370-25-004068.md) | [2.63](/filings/0001104659-26-034554.md) | [(22.61)](/filings/0001104659-26-034554.md) | | Free cash flow | $m | [(9.3)](/filings/0001558370-23-003167.md) | [(17.0)](/filings/0001558370-24-004532.md) | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pmn/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $17.0m | 1,292,757 | | Not compared | | [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $16.4m | 1,292,757 | | Not compared | | [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $11.0m | 835,655 | | Unchanged | | [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $9.2m | 696,378 | | Unchanged | | [Ally Bridge Group (NY) LLC](/funds/1822947.md) | 2026-06-30 | $8.2m | 620,319 | | Added +206,100 | | [Trails Edge Capital Partners, LP](/funds/2077247.md) | 2026-06-30 | $7.3m | 557,103 | | Unchanged | | [Woodline Partners LP](/funds/1784547.md) | 2026-06-30 | $5.8m | 441,911 | | Added +46,616 | | [Yu Fan](/funds/1668029.md) | 2026-06-30 | $4.3m | 329,760 | | Unchanged | | [SPHERA FUNDS MANAGEMENT LTD.](/funds/1496201.md) | 2026-06-30 | $4.3m | 325,591 | | Unchanged | | [Squadron Capital Management LLC](/funds/2050709.md) | 2026-06-30 | $4.3m | 324,977 | | Unchanged | ## Recent filings [All 357 filings](/companies/pmn/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-13 | 20:07 ET | [8-K](/filings/0001104659-26-095905.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-095905 | | 2026-08-13 | 20:06 ET | [10-Q](/filings/0001104659-26-095895.md) | Quarterly report, period 2026-06-30 | 0001104659-26-095895 | | 2026-07-28 | 10:05 ET | [8-K](/filings/0001104659-26-087269.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-087269 | | 2026-05-20 | 20:30 ET | [8-K](/filings/0001104659-26-064545.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-064545 | | 2026-05-12 | 12:15 ET | [10-Q](/filings/0001104659-26-059035.md) | Quarterly report, period 2026-03-31 | 0001104659-26-059035 | | 2026-05-12 | 10:45 ET | [8-K](/filings/0001104659-26-058967.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-058967 | | 2026-04-09 | 20:01 ET | [DEF 14A](/filings/0001104659-26-041483.md) | Proxy statement, period 2026-05-20 | 0001104659-26-041483 | | 2026-03-25 | 20:34 ET | [10-K](/filings/0001104659-26-034554.md) | Annual report, period 2025-12-31 | 0001104659-26-034554 | | 2026-03-25 | 12:06 ET | [8-K](/filings/0001104659-26-034162.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-034162 | | 2026-02-05 | 00:02 ET | [SCHEDULE 13D/A](/filings/0001493152-26-005412.md) | Ownership report, active investor, amended | 0001493152-26-005412 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-034554.md), filed Mar 25, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1374339 - Tickers: PMN - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: Z4 - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.